Adjuvant Hormone Therapy in Breast Cancer

References

• EBCTCG. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials of 28,896 women. N Engl J Med 1988; 319: 1681–92
   PubMed Web of Science ®Google Scholar
• EBCTCG. Treatment of early breast cancer. Worldwide evidence 1985–1990. Oxford University Press, Oxford 1990; 209
   Google Scholar
• EBCTCG. Systemic treatment of early breast cancer by hormonal, cytotocis, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; i: 1–15; 71–85
   Google Scholar
• Rutqvist L E, Cedermark B, Fomander T, et al. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 1989; 7: 1474–84
   PubMed Web of Science ®Google Scholar
• Rutqvist L E, Cedermark B, Glas U, et al. Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 1990; 66: 89–96
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Gelber R. Adjuvant treatment for early breast cancer: The Ludwig breast cancer studies. NCI Monograph 1986; 55–70
   Google Scholar
• Controlled trial of tamoxifen as a single agent in the management of early breast cancer. Analysis of eight years by ‘Nolvadex’ adjuvant trial organisation. Br J Cancer 1988; 57: 608–11
   Google Scholar
• Mouridsen H T, Rose C, Overgaard M, et al. Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. Acta Oncol 1988; 27: 699–705
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Overgaard M. The role of adjuvant radiotherapy added to systemic therapy. 15th International Cancer Congress, Hamburg, 1990; 1123, (abstract)
   Google Scholar
• Fisher B, Constantino J, Redmond C, et al. A randomized trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479–84
   PubMed Web of Science ®Google Scholar
• DeVita V T. Breast cancer therapy: Exercising all our options. N Engl J Med 1989; 320: 527–9
   PubMed Web of Science ®Google Scholar
• McGuire W L. Adjuvant therapy of node-negative breast cancer. N Engl J Med 1989; 320: 525–7
   PubMed Web of Science ®Google Scholar
• Rose C, Thorpe S M, Andersen K W, et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985; 1: 16–19
   PubMed Web of Science ®Google Scholar
• Thorpe S. Prognostic value of hormone receptors and adjuvant effect in the DBCG studies, 199: 5, Haikko: Fourth Scandinavian Breast Cancer Symposium (abstract)
   Google Scholar
• Stewart H J. The Scottish adjuvant tamoxifen trials. Treatment of early stage breast cancer. NIH Consensus Development Conference. June, 18–211990, 65–70, (abstract)
   Google Scholar
• Fornander T, Cedermark B, Mattson A, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117–9
   PubMed Web of Science ®Google Scholar
• Bagdade J D, Wolter J, Subbaiih P V, Ryan W. Effects of tamoxifen treatment on plasma lipids and lipoprotein composition. J Clin Endocrinol Metab 1990; 70: 1132–5
   PubMed Web of Science ®Google Scholar
• Bertelli G, Pronzato P, Amoroso D, et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988; 12: 307–10
   PubMed Web of Science ®Google Scholar
• Bruning P F, Bonfrer J M, Hart A A, et al. Tamoxifen, serumlipoproteins and cardiovascular risk. Br J Cancer 1988; 58: 497–9
   PubMed Web of Science ®Google Scholar
• Longstaff S, Sigurdsson H, O'Keeffe M, Ogston S, Preece P. A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast ca rcinoma. Eur J Cancer Clin Oncol 1989; 25: 1805–8
   PubMedGoogle Scholar
• Fornander T, Rutqvist L E, Sjöberg H E, Blomqvist L, Mattson A, Glas U. Long term adjuvant tamoxifen in early breast cancer: Effect of bone mineral density in postmenopausal women. J Clin Oncol 1980; 8: 1019–24
   Google Scholar
• Gotfredsen A, Christiansen C, Palshof T. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 1984; 53: 853–7
   Google Scholar
• Fentiman I S, Caleffi M, Rodidn A, Murby B, Fogelman I. Bone mineral content of women receiving tamoxifen for mastalgia. Br J Cancer 1989; 60: 262–4
   Google Scholar